Value of serum-soluble intercellular adhesion molecule-1 for the noninvasive risk assessment of transplant coronary artery disease, posttransplant ischemic events, and cardiac graft failure

Carlos A. Labarrere, David R. Nelson, Steven Miller, Jennifer M. Nieto, Jennifer A. Conner, Douglas E. Pitts, Philip C. Kirlin, Harold G. Halbrook

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background - Adhesion molecules on arterial endothelium have been implicated in spontaneous atherosclerosis and transplant coronary artery disease (CAD). We studied whether elevated serum-soluble intercellular adhesion molecule-1 (sICAM-1) during the immediate posttransplant period was a risk factor for CAD, posttransplant ischemic events, or cardiac graft failure. Methods and Results - We initially studied serum sICAM-1 in a subset of 16 cardiac allograft recipients (5.5 ± 0.7 samples per patient) to determine a cutoff point that best correlated with presence of arterial and arteriolar endothelial ICAM-1 in matching endomyocardial biopsies. The cutoff value was 308 ng/mL. Subsequently, we prospectively evaluated serum sICAM-1 in serial samples (5.3 ± 0.1 per patient) obtained during the first 3 months after transplantation in a validation subset of 130 recipients and correlated early sICAM-1 levels with long-term outcome. Serum sICAM-1 >308 ng/mL correlated significantly with ICAM-1 on arterial find arteriolar endothelium (P=0.02). Cardiac allograft recipients with serum sICAM-1 >308 ng/mL had 2.67 (95% CI, 1.28 to 5.59, P=0.009) times greater risk of CAD and 3.63 (95% CI, 1.05 to 12.5, P=0.04) times greater risk of graft failure. Recipients with sICAM-1 >308 ng/mL also developed more severe CAD (P=0.009) and more ischemic events (P=0.03) after transplantation. Conclusions - Serum sICAM-1 levels can be used to noninvasively assess risk of transplant CAD, posttransplant ischemic events, and cardiac graft failure.

Original languageEnglish
Pages (from-to)1549-1555
Number of pages7
JournalCirculation
Volume102
Issue number13
StatePublished - Sep 26 2000

Fingerprint

Intercellular Adhesion Molecule-1
Coronary Artery Disease
Heart Failure
Transplants
Serum
Endothelium
Allografts
Transplantation
Atherosclerosis
Biopsy

Keywords

  • Cell adhesion molecules
  • Coronary disease
  • Heart failure
  • Risk factors
  • Transplantation

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Value of serum-soluble intercellular adhesion molecule-1 for the noninvasive risk assessment of transplant coronary artery disease, posttransplant ischemic events, and cardiac graft failure. / Labarrere, Carlos A.; Nelson, David R.; Miller, Steven; Nieto, Jennifer M.; Conner, Jennifer A.; Pitts, Douglas E.; Kirlin, Philip C.; Halbrook, Harold G.

In: Circulation, Vol. 102, No. 13, 26.09.2000, p. 1549-1555.

Research output: Contribution to journalArticle

Labarrere, Carlos A. ; Nelson, David R. ; Miller, Steven ; Nieto, Jennifer M. ; Conner, Jennifer A. ; Pitts, Douglas E. ; Kirlin, Philip C. ; Halbrook, Harold G. / Value of serum-soluble intercellular adhesion molecule-1 for the noninvasive risk assessment of transplant coronary artery disease, posttransplant ischemic events, and cardiac graft failure. In: Circulation. 2000 ; Vol. 102, No. 13. pp. 1549-1555.
@article{0f22d49c3a5d4921a652ad7d3c54e25d,
title = "Value of serum-soluble intercellular adhesion molecule-1 for the noninvasive risk assessment of transplant coronary artery disease, posttransplant ischemic events, and cardiac graft failure",
abstract = "Background - Adhesion molecules on arterial endothelium have been implicated in spontaneous atherosclerosis and transplant coronary artery disease (CAD). We studied whether elevated serum-soluble intercellular adhesion molecule-1 (sICAM-1) during the immediate posttransplant period was a risk factor for CAD, posttransplant ischemic events, or cardiac graft failure. Methods and Results - We initially studied serum sICAM-1 in a subset of 16 cardiac allograft recipients (5.5 ± 0.7 samples per patient) to determine a cutoff point that best correlated with presence of arterial and arteriolar endothelial ICAM-1 in matching endomyocardial biopsies. The cutoff value was 308 ng/mL. Subsequently, we prospectively evaluated serum sICAM-1 in serial samples (5.3 ± 0.1 per patient) obtained during the first 3 months after transplantation in a validation subset of 130 recipients and correlated early sICAM-1 levels with long-term outcome. Serum sICAM-1 >308 ng/mL correlated significantly with ICAM-1 on arterial find arteriolar endothelium (P=0.02). Cardiac allograft recipients with serum sICAM-1 >308 ng/mL had 2.67 (95{\%} CI, 1.28 to 5.59, P=0.009) times greater risk of CAD and 3.63 (95{\%} CI, 1.05 to 12.5, P=0.04) times greater risk of graft failure. Recipients with sICAM-1 >308 ng/mL also developed more severe CAD (P=0.009) and more ischemic events (P=0.03) after transplantation. Conclusions - Serum sICAM-1 levels can be used to noninvasively assess risk of transplant CAD, posttransplant ischemic events, and cardiac graft failure.",
keywords = "Cell adhesion molecules, Coronary disease, Heart failure, Risk factors, Transplantation",
author = "Labarrere, {Carlos A.} and Nelson, {David R.} and Steven Miller and Nieto, {Jennifer M.} and Conner, {Jennifer A.} and Pitts, {Douglas E.} and Kirlin, {Philip C.} and Halbrook, {Harold G.}",
year = "2000",
month = "9",
day = "26",
language = "English",
volume = "102",
pages = "1549--1555",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "13",

}

TY - JOUR

T1 - Value of serum-soluble intercellular adhesion molecule-1 for the noninvasive risk assessment of transplant coronary artery disease, posttransplant ischemic events, and cardiac graft failure

AU - Labarrere, Carlos A.

AU - Nelson, David R.

AU - Miller, Steven

AU - Nieto, Jennifer M.

AU - Conner, Jennifer A.

AU - Pitts, Douglas E.

AU - Kirlin, Philip C.

AU - Halbrook, Harold G.

PY - 2000/9/26

Y1 - 2000/9/26

N2 - Background - Adhesion molecules on arterial endothelium have been implicated in spontaneous atherosclerosis and transplant coronary artery disease (CAD). We studied whether elevated serum-soluble intercellular adhesion molecule-1 (sICAM-1) during the immediate posttransplant period was a risk factor for CAD, posttransplant ischemic events, or cardiac graft failure. Methods and Results - We initially studied serum sICAM-1 in a subset of 16 cardiac allograft recipients (5.5 ± 0.7 samples per patient) to determine a cutoff point that best correlated with presence of arterial and arteriolar endothelial ICAM-1 in matching endomyocardial biopsies. The cutoff value was 308 ng/mL. Subsequently, we prospectively evaluated serum sICAM-1 in serial samples (5.3 ± 0.1 per patient) obtained during the first 3 months after transplantation in a validation subset of 130 recipients and correlated early sICAM-1 levels with long-term outcome. Serum sICAM-1 >308 ng/mL correlated significantly with ICAM-1 on arterial find arteriolar endothelium (P=0.02). Cardiac allograft recipients with serum sICAM-1 >308 ng/mL had 2.67 (95% CI, 1.28 to 5.59, P=0.009) times greater risk of CAD and 3.63 (95% CI, 1.05 to 12.5, P=0.04) times greater risk of graft failure. Recipients with sICAM-1 >308 ng/mL also developed more severe CAD (P=0.009) and more ischemic events (P=0.03) after transplantation. Conclusions - Serum sICAM-1 levels can be used to noninvasively assess risk of transplant CAD, posttransplant ischemic events, and cardiac graft failure.

AB - Background - Adhesion molecules on arterial endothelium have been implicated in spontaneous atherosclerosis and transplant coronary artery disease (CAD). We studied whether elevated serum-soluble intercellular adhesion molecule-1 (sICAM-1) during the immediate posttransplant period was a risk factor for CAD, posttransplant ischemic events, or cardiac graft failure. Methods and Results - We initially studied serum sICAM-1 in a subset of 16 cardiac allograft recipients (5.5 ± 0.7 samples per patient) to determine a cutoff point that best correlated with presence of arterial and arteriolar endothelial ICAM-1 in matching endomyocardial biopsies. The cutoff value was 308 ng/mL. Subsequently, we prospectively evaluated serum sICAM-1 in serial samples (5.3 ± 0.1 per patient) obtained during the first 3 months after transplantation in a validation subset of 130 recipients and correlated early sICAM-1 levels with long-term outcome. Serum sICAM-1 >308 ng/mL correlated significantly with ICAM-1 on arterial find arteriolar endothelium (P=0.02). Cardiac allograft recipients with serum sICAM-1 >308 ng/mL had 2.67 (95% CI, 1.28 to 5.59, P=0.009) times greater risk of CAD and 3.63 (95% CI, 1.05 to 12.5, P=0.04) times greater risk of graft failure. Recipients with sICAM-1 >308 ng/mL also developed more severe CAD (P=0.009) and more ischemic events (P=0.03) after transplantation. Conclusions - Serum sICAM-1 levels can be used to noninvasively assess risk of transplant CAD, posttransplant ischemic events, and cardiac graft failure.

KW - Cell adhesion molecules

KW - Coronary disease

KW - Heart failure

KW - Risk factors

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=0034718515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034718515&partnerID=8YFLogxK

M3 - Article

VL - 102

SP - 1549

EP - 1555

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 13

ER -